![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Corrected Proof)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
![[thumbnail of Supplemental Material]](https://mdc-test.eprints-hosting.org/style/images/fileicons/other.png) |
Other (Supplemental Material)
313kB |
| Item Type: | Article |
|---|---|
| Title: | Novel tryptophan hydroxylase inhibitor TPT-001 reverses PAH, vascular remodeling, and proliferative-proinflammatory gene expression |
| Creators Name: | Legchenko, E., Chouvarine, P., Qadri, F., Specker, E., Nazaré, M., Wesolowski, R., Matthes, S., Bader, M. and Hansmann, G. |
| Abstract: | The serotonin pathway has long been proposed as a promising target for pulmonary arterial hypertension (PAH)—a progressive and uncurable disease. We developed a highly specific inhibitor of the serotonin synthesizing enzyme tryptophan hydroxylase 1 (TPH1), TPT-001 (TPHi). In this study, the authors sought to treat severe PAH in the Sugen/hypoxia (SuHx) rat model with the oral TPHi TPT-001. Male Sprague Dawley rats were divided into 3 groups: 1) ConNx, control animals; 2) SuHx, injected subcutaneously with SU5416 and exposed to chronic hypoxia for 3 weeks, followed by 6 weeks in room air; and 3) SuHx+TPHi, SuHx animals treated orally with TPHi for 5 weeks. Closed-chest right- and left heart catheterization and echocardiography were performed. Lungs were subject to histologic and mRNA sequencing analyses. Compared with SuHx-exposed rats, which developed severe PAH and right ventricular (RV) dysfunction, TPHi-treated SuHx rats had greatly lowered RV systolic (mean ± SEM: 41 ± 2.3 mm Hg vs 86 ± 6.5 mm Hg; P < 0.001) and end-diastolic (mean ± SEM: 4 ± 0.7 mm Hg vs 14 ± 1.7 mm Hg; P < 0.001) pressures, decreased RV hypertrophy and dilation (all not significantly different from control rats), and reversed pulmonary vascular remodeling. We identified perivascular infiltration of CD3(+) T cells and proinflammatory F4/80(+) and CD68(+) macrophages and proliferating cell nuclear antigen–positive alveolar epithelial cells all suppressed by TPHi treatment. Whole-lung mRNA sequencing in SuHx rats showed distinct gene expression patterns related to pulmonary arterial smooth muscle cell proliferation (Rpph1, Lgals3, Gata4), reactive oxygen species, inflammation (Tnfsrf17, iNOS), and vasodilation (Pde1b, Kng1), which reversed expression with TPHi treatment. Inhibition of TPH1 with a new class of drugs (here, TPT-001) has the potential to attenuate or even reverse severe PAH and associated RV dysfunction in vivo by blocking the serotonin pathway. |
| Keywords: | Drug Discovery, Pulmonary Arterial Hypertension, Serotonin, Tryptophan Hydroxylase Inhibitor, Animals, Mice, Rats |
| Source: | JACC: Basic to Translational Science |
| ISSN: | 2452-302X |
| Publisher: | American College of Cardiology |
| Volume: | 9 |
| Number: | 7 |
| Page Range: | 890-902 |
| Date: | July 2024 |
| Official Publication: | https://doi.org/10.1016/j.jacbts.2024.04.006 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
